Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study
Elizabeth Stenger(Emory University), Allistair Abraham(Children's National), Rikin Shah(Center for Children), Kimberly A. Kasow(University of North Carolina at Chapel Hill), Monica Bhatia(Columbia University Irving Medical Center), Yijin Xiang(Emory University), Scott Gillepsie, Lakshmanan Krishnamurti(Emory University), John Horan(Emory University), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Michael J. Eckrich(Levine Children's Hospital), Sonali Chaudhury(Northwestern University), Gregory M.T. Guilcher(University of Calgary), Alexander Ngwube(Children's Cancer Center), Jennifer Jaroscak(Medical University of South Carolina), Shalini Shenoy(Washington University in St. Louis), Deepak Chellapandian(Johns Hopkins University), Tim S. Olson, Jennifer Krajewski
Cited by 1
Related Papers
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease
|American Journal of Respiratory and Critical Care Medicine|2014|256
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|255
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248